How the Cyprus IP Box is calculated: the nexus fraction explained (2026)

How is the Cyprus IP Box calculated?

The Cyprus IP Box is calculated by multiplying the net income from a qualifying asset by the nexus fraction to find the qualifying profit, deducting 80% of that profit, and taxing only the remaining 20% at the 15% corporate income tax rate. The more of your research and development (R&D) you carried out yourself, the higher the fraction and the lower your effective tax.

In sequence, the calculation runs: overall income (OI) × nexus ratio = qualifying profit; then qualifying profit − 80% deduction = taxable IP profit; then taxable IP profit × 15% = tax due. Where the nexus ratio is 100%, the headline effective rate on qualifying IP income is roughly 3%.

The nexus fraction is the mechanism that ties the tax benefit to substance. It follows the OECD's modified nexus approach, so the relief you receive is proportionate to the economic activity you actually performed in creating the intellectual property.

• Step 1: determine overall income (OI) from the qualifying asset.
• Step 2: calculate the nexus ratio = (QE + UE) ÷ OE, capped at 100%.
• Step 3: qualifying profit = OI × nexus ratio.
• Step 4: apply the 80% deduction, leaving 20% taxable.
• Step 5: tax the remainder at 15%.

The four terms you need: OI, QE, UE and OE

Every figure in the Cyprus IP Box formula reduces to four defined terms, and getting the classification right is where most of the tax outcome is decided.

Overall income (OI) is the net income the qualifying asset produces, after deducting directly related expenses. Overall expenditure (OE) is the total of all R&D spend on the asset, including costs that do not qualify. Qualifying expenditure (QE) is the subset of that spend which counts in your favour, and the uplift expenditure (UE) is a bonus added on top of QE.

• OI (overall income): net income from the qualifying IP — royalties, embedded IP income, licensing and gains — after related costs.
• QE (qualifying expenditure): your own in-house R&D plus R&D outsourced to unrelated third parties. This counts even if the work was performed abroad.
• UE (uplift expenditure): a 30% top-up on QE, capped so it can never exceed the excluded costs below.
• OE (overall expenditure): QE plus acquisition cost of the IP plus R&D outsourced to related parties.
• Excluded from QE (and added to OE): the cost of acquiring the IP and any R&D paid to related/group companies.

The nexus fraction, step by step

The nexus fraction is (QE + UE) ÷ OE, capped at 100%. It expresses the proportion of your development effort that Cyprus treats as genuine substance, and it directly scales the profit that can enjoy the 80% deduction.

Because acquisition costs and related-party R&D sit only in the denominator (OE) and never in QE, relying on bought-in IP or group R&D pushes the fraction down. Conversely, a company that develops its own asset in-house has QE equal to OE, so the fraction is 100% before the uplift is even considered.

The cap at 100% matters: the 30% uplift can lift a partly-outsourced or partly-acquired asset back towards full benefit, but it can never take the fraction above 1. The uplift is a smoothing tool, not a way to manufacture relief beyond your actual profit.

• Numerator: QE + UE (your qualifying spend plus the 30% uplift).
• Denominator: OE (everything spent on the asset).
• Uplift = the lower of 30% of QE, or the total of acquisition cost + related-party R&D.
• Result is capped at 100% — never more.
• Pure in-house development ⇒ fraction = 100%.

Why the 30% uplift exists

The 30% uplift exists to stop the nexus rules from punishing normal, commercially sensible business decisions. A modest amount of acquisition or group R&D would otherwise sharply cut the fraction, even where the company did most of the real work itself.

So the rule adds up to 30% of your qualifying expenditure back into the numerator — but only up to the amount of the costs that were excluded from QE (acquisition plus related-party R&D). If you had no excluded costs, there is nothing for the uplift to compensate for, and it contributes nothing.

In practice the uplift means a business can acquire a foundational asset or use a group R&D centre for part of a project and still reach, or nearly reach, the full benefit — provided the bulk of the value was created through its own or unrelated-party effort.

• Uplift = min(30% × QE, acquisition cost + related-party R&D).
• It only helps where excluded costs exist.
• It cannot push the nexus fraction above 100%.
• Purpose: fair treatment of mixed-source development, not a loophole.

Worked example (a): internally developed IP → ~3%

A Cyprus software company builds its product entirely in-house with its own developers. There is no acquisition cost and no related-party R&D, so qualifying expenditure equals overall expenditure and the nexus fraction is 100%.

Take net IP income (OI) of €1,000,000. The nexus ratio is 100%, so the qualifying profit is the full €1,000,000. The 80% deduction removes €800,000, leaving €200,000 taxable. At 15% corporate income tax, the tax due is €30,000 — an effective rate of about 3% on the IP income.

• OI: €1,000,000
• QE = OE (all own R&D) ⇒ nexus ratio = 100%
• Qualifying profit: €1,000,000 × 100% = €1,000,000
• 80% deduction: −€800,000 ⇒ taxable €200,000
• Tax at 15%: €30,000 → effective rate ≈ 3%

Worked example (b): acquired IP plus third-party R&D → partial benefit

Now take a company that acquired a base asset and then developed it further using its own team and unrelated subcontractors. This is the classic mixed case, and it is worth walking through the numbers in full.

Assume net IP income (OI) of €1,000,000. Qualifying expenditure (QE) — own plus unrelated-party R&D — is €400,000. The excluded costs are €300,000 (the acquisition cost). Overall expenditure (OE) is therefore €700,000.

The uplift is the lower of 30% of QE (€120,000) or the excluded costs (€300,000), so the uplift is €120,000. The numerator is QE + UE = €400,000 + €120,000 = €520,000. The nexus ratio is €520,000 ÷ €700,000 ≈ 74%.

Qualifying profit is €1,000,000 × 74% = €740,000. The 80% deduction removes €592,000, leaving €148,000 taxable. Tax at 15% is €22,200 — an effective rate of about 2.2% on that qualifying slice, while the non-qualifying €260,000 of income is taxed normally at 15%.

• OI: €1,000,000
• QE (own + unrelated R&D): €400,000
• Excluded costs (acquisition): €300,000 ⇒ OE = €700,000
• Uplift: min(30% × €400,000 = €120,000, €300,000) = €120,000
• Numerator: €400,000 + €120,000 = €520,000
• Nexus ratio: €520,000 ÷ €700,000 ≈ 74%
• Qualifying profit: €740,000; after 80% deduction, €148,000 taxable; tax €22,200

Worked example (c): acquired IP plus related-party R&D → little or no benefit

Finally, consider a company that acquired the IP and had all further development carried out by a related group entity. Here almost nothing lands in qualifying expenditure: acquisition cost and related-party R&D are both excluded from QE and sit only in overall expenditure.

If QE is near zero and OE is, say, €700,000, the uplift (30% of a near-zero QE) is also near zero. The nexus ratio collapses towards 0%, so there is little or no qualifying profit and therefore no 80% deduction. The IP income is effectively taxed at the standard 15% corporate rate.

This is the intended result of the nexus approach: a company that neither developed the asset itself nor used unrelated parties has not created the substance the regime rewards, so it does not receive the benefit.

• OI: €1,000,000
• QE (own + unrelated R&D): ≈ €0
• OE (acquisition + related-party R&D): €700,000
• Uplift: ≈ €0 (30% of near-zero QE)
• Nexus ratio: ≈ 0% ⇒ negligible qualifying profit
• Result: income taxed at the standard 15% — no meaningful IP Box benefit

Other points that affect the calculation

Two further features shape the outcome. First, capital gains on the disposal of a qualifying IP asset are exempt — a 0% rate — and are not clawed into the nexus calculation. Second, the nexus fraction is tracked per asset (or per product where assets are linked), so a business with several IP assets runs the formula separately for each.

It is also worth noting the historical shift: the effective rate is often quoted as 2.5%, which reflected the pre-2026 12.5% corporate rate. From 2026 the corporate rate is 15%, so the same 80% deduction now produces an effective rate of about 3%. The mechanics are unchanged; only the headline corporate rate moved.

• Capital gains on qualifying IP disposals: 0%.
• Nexus tracking is per asset (or per product).
• Effective rate ≈ 3% from 2026 (was 2.5% under the old 12.5% rate).
• Keep documentation linking each euro of spend to the right term (QE, OE, excluded).